CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing ACD856, a novel small molecule aimed at treating Alzheimer's Disease by enhancing neurotrophic pathways essential for cognitive function. This oral medication aims to improve cognitive abilities and potentially modify disease progression, with plans for Phase II clinical trials to demo…
Alzheimer’s Disease (AD) is a growing public health crisis, affecting millions of people worldwide with a steady cognitive decline.
Current treatments offer only temporary symptomatic relief and fail to address the underlying disease progression.
As the population ages, the prevalence of AD is expected to double by 2050, placing an immense burden on caregivers and healthcare systems struggling to provide long-term care.AlzeCure, a clinical-stage biotech company, has developed ACD856, a first-in-…
AlzeCurePharma AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
